Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Leading homebuilder DR Horton Inc. (DHI - Analyst Report) reported adjusted net earnings (excluding inventory impairments and land option write-off costs) of 12 cents per share in the second quarter of fiscal 2012 versus 3 cents per share in the year-ago quarter. Earnings per share largely outperformed the Zacks Consensus Estimate of 4 cents. The earnings upsurge was driven by strong operating results in both the homebuilding and financial services segments.
Homebuilding revenues climbed 28.0% year over year to $935.6 million, driven by double-digit growth in net sales orders, homes closed and sales order backlog. Reported revenues also beat the Zacks Consensus Estimate of $840 million by a wide margin.
Quarter in Detail
Home sales increased 27.0% year over year to $930.6 million, driven by strong growth in net sales orders. On the other hand, land sales contributed $5.0 million to revenues compared with a measly $0.1 million in the prior year.
Net sales orders in the second quarter totaled 5,899 homes (valued at $1.3 billion), up 19% in terms of numbers over the prior-year quarter. Net sales orders also jumped approximately 55% sequentially. Home closings were up 21.0% to 4,240 homes in the reported quarter compared with 3,516 homes a year ago.
The quarter-end sales order backlog rose 17% to 6,189 homes, amounting to $1.4 billion, from 5,281 homes valued at $1.1 billion at the end of the second quarter of 2011. Sales order backlog represents homes under contract but not yet closed at the end of a certain period.
Gross profit on home sales was $163.4 million versus $119.1 million in the prior-year quarter. Selling, general & administrative (SG&A) expenses were 13.6% of homebuilding revenue versus 16.8% in the prior-year quarter as the company leveraged its fixed costs. Operating income from financial services came in at $7.7 million versus $1.6 million in the prior-year quarter. Consolidated pretax income was thus $42.3 million in the quarter compared with a pre-tax loss of $30.8 million in the prior-year quarter.
DR Horton’s homebuilding cash, cash equivalents and marketable securities totaled $961.3 million as of March 31, 2012, versus 1.06 billion at the end of December 30, 2011.
Dividend Announcement
The company announced that it will pay a quarterly cash dividend of $0.0375 per share on May 22, 2012 to shareholders of record on May 8, 2012.
Outlook
The company retained its first-quarter momentum in the second quarter, too, with yet another earnings beat. DR Horton had started the financial year on a strong note despite macroeconomic uncertainties and housing conditions remaining soft. The company expects to be profitable in the next half of the fiscal year as well.
Management expects stronger home closings in the third and fourth quarters of fiscal 2012 as demand for new homes historically ramp in the latter half of the year. Gross margin is expected be in the mid-16%-mid17% range in 2012. SG&A is expected to increase in the third and fourth quarters of 2012. However, SG&A as a percentage of revenue will gradually improve in these quarters due to strong home closings and better fixed cost leverage.
Our Recommendation
We currently have a Neutral recommendation on DR Horton. The stock carries a Zacks #3 Rank in the near term (Hold rating).
The last few years have seen a very fragile housing market. The downturn in the housing industry – aggravated by an overall weak economy, high unemployment rates, low consumer confidence, rising interest rates and tightened mortgage lending standards– has been weighing down on homebuilders like DR Horton and its compatriots KB Home (KBH - Analyst Report), Pulte Group (PHM - Analyst Report) and Lennar Corporation (LEN - Analyst Report). Declining demand for new homes and an excess of supply in the market in 2011 drove DR Horton to make large concessions in prices.
Come 2012, there has been a definite improvement in demand in the homebuilding sector. The company’s strong performance in the first half is a testament to the fact. Moreover, DR Horton enjoys strong cash flows which are helpful in paying back outstanding debts. All said, we would still prefer to remain on the sidelines until we witness a speedy recovery in the overall housing market.
Get the full Analyst Report on DHI - FREE
Get the full Analyst Report on PHM - FREE
Get the full Analyst Report on LEN - FREE
Get the full Analyst Report on KBH - FREE